Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Multiple Sclerosis Market Competitive Landscape Report 2026: Comprehensive Insights on Over 60 Companies and 75 Drugs by Product Type, Development Stage, Administration Route, and Molecule Type

globenewswire.com
SNY Sanofi is listed as a key player in the competitive landscape of Multiple Sclerosis treatments, indicating its involvement in the market without specific positive or negative performance indicators. IMUX Immunic is mentioned as a key player with a pipeline product (IMU-838) in mid-stage development for Multiple Sclerosis, suggesting ongoing research and development in the sector. TLSA Tiziana Life Sciences is identified as a company with a pipeline product (Foralumab) in mid-stage development for Multiple Sclerosis, indicating its participation in the MS therapeutic landscape. BIIB Biogen is listed as a key player in the Multiple Sclerosis market, suggesting its established presence and involvement in the development or marketing of MS therapies. TGTX TG Therapeutics is featured with a marketed therapy (BRIUMVI) for Multiple Sclerosis, indicating its presence and contribution to the current treatment options available.

Multiple Sclerosis Market Competitive Landscape Report 2026: Comprehensive Insights on Over 60 Companies and 75 Drugs by Product Type, Development Stage, Administration Route, and Molecule Type Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.

The report offers comprehensive insights on over 60 companies and 75 drugs targeting Multiple Sclerosis (MS). It provides a thorough analysis of therapeutics by product type, development stage, administration route, and molecule type, also addressing inactive pipeline products globally.

Multiple Sclerosis is a prevalent neurological disorder among young adults, affecting the axons in the central nervous system. Primarily impacting individuals aged 20-40, it is diagnosed in around 2.5 million people worldwide, with a higher incidence in females. Disease-modifying therapies (DMT) are essential in managing MS, alongside symptomatic relief therapies. Currently, 12 DMTs are FDA-approved, including notable treatments like Tecfidera, Lemtrada, Plegridy, and Copaxone since 2013.

For further insights, the report delivers an in-depth commercial assessment of MS drugs focusing on collaborations, licensing, and acquisitions among key players. Key questions are addressed, including the development status of drugs, collaboration strategies, and trends in MS therapeutics.

Key Players in this landscape include Sanofi, Immunic, Tiziana Life Sciences, Biogen, J-Pharma, and Bristol-Myers Squibb among others. The report also examines emerging products such as SAR 441344, IMU-838, and foralumab.

Report Highlights

Key Company and Product Profiles

Key Topics Covered:

Introduction

Executive Summary

Multiple Sclerosis: Overview

Multiple Sclerosis -Analytical Perspective: In-depth Commercial Assessment

Competitive Landscape

Therapeutic Assessment

Multiple Sclerosis: Company and Product Profiles (Marketed Therapies)

TG Therapeutics

BRIUMVI

Multiple Sclerosis: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Phase III)

Immunic

IMU-838

Mid Stage Products (Phase II)

Tiziana Life Sciences

Foralumab

Early Stage Products (Phase I)

J-Pharma Co., Ltd.

JPH034

Preclinical and Discovery Stage Products

Polpharma Biologics

PB018

Inactive Products

Multiple Sclerosis- Unmet needs

Multiple Sclerosis - Market drivers and barriers

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/x37obh

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.